Get those blood tests (AMERK and ctDNA) going for MCC patients! Super helpful for surveillance and early recurrence detection, and provides a lot of peace of mind for both patients and clinicians.
@mc3-institute.bsky.social @paulnghiem.bsky.social
@lachancekrista.bsky.social
Peter Ch’en
In this cohort study of Merkel cell #carcinoma patients, a falling or negative titer indicated a 99.3% chance of remaining recurrence-free over 3 months, while a rising oncoprotein antibody titer suggested a 58% risk of recurrence by 12 months. ja.ma/4rifJeA
